AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06700655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal transplantation
Description: The patient awaited allogeneic corneal donation and underwent corneal transplantation surgery.
Study NCT06700655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cornea limbal stem cell transplantation combined corneal stromal stem cell group
Description: The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells and corneal stromal stem cells.
Study NCT06702163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (active)
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more.
Study NCT06702163 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (sham)
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study NCT05820542 — intervention group
Intervention type: OTHER
Intervention: miller laryngoscope
Description: The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
Study NCT06701201 — intervention group
Intervention type: DRUG
Intervention: SynKIR-110
Description: Autologous T cells Transduced with Mesothelin KIR-CAR
Study NCT06701201 — intervention group
Intervention type: DRUG
Intervention: SynKIR-310
Description: Autologous T Cells transduced with CD19 KIR-CAR
Study NCT06701708 — intervention group
Intervention type: OTHER
Intervention: Participants are not assigned to interventions based on a protocol.
Description: Participants are not assigned to interventions based on a protocol.
Study NCT06703177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1826
Description: SHR-1826
Study NCT06703177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4642
Description: SHR-4642
Study NCT06703177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839
Description: SHR-9839
Study NCT06703177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: SHR-8068
Study NCT06703177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Bevacizumab Injection
Study NCT06703177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil Injection
Description: Fluorouracil Injection
Study NCT06703177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate Injection
Description: Calcium Folinate Injection
Study NCT06703177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab Injection
Description: Adebrelimab Injection
Study NCT06397794 — intervention group
Intervention type: OTHER
Intervention: Quantitative surveys and qualitative interview
Description: All participants will complete online surveys on topics including demographic and socioeconomic information, medical history (parent and child), pregnancy history, and mental health and well-being. They will then participate in a qualitative interview about their pregnancy and parenting experiences as gestational parents with Lyme disease.
Study NCT05968612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet
Description: Film-coated tablet administered orally.
Study NCT05968612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor 200 mg Film-Coated Tablet Formulation
Description: Film-coated tablet administered orally.
Study NCT05014009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIFA11+ and multidirectional training (MD)
Description: This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time.
Study NCT05014009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FIFA11+ and linear sprint training (MD)
Description: This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time.
Study NCT05831293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program
Description: In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
Study NCT06704048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Standard hospital-based cardiac rehabilitation according to SEPHIA and SWEDEHEART protocols 2 times a week for 12 weeks with individualized physical evaluation before and after the intervention.
Study NCT06702605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004 tablets
Description: XNW5004 will be administered orally as tablets.
Study NCT06703372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diode Laser 980 nm, 0.2W
Description: diode laser will be used at an operating wavelength of 980 nm, with adoption of the due safety measures in all cases. Laser irradiation will be applied bilaterally to the skin over the area of the submandibular and parotid glands. Irradiation will be applied externally to the parotid gland on a continuous basis and likewise to the submandibular gland moving the laser very slowly over the gland zone
Study NCT06703372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diode laser
Description: the tip of the instrument will be sealed with blue rubber to prevent the passage of light
Study NCT06704035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Early OGTT Results Revealed
Description: Early pregnancy screening with a three-time point (fasting, 1h, 2h) 75g oral glucose tolerance test before 16 weeks' gestation with plasma glucose results revealed to the patient and clinician for appropriate management of any diabetes (gestational and type 2, if diagnosed) from early pregnancy onwards.
Study NCT06702956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser corticotomy
Description: stimulation of tooth movement during orthodontics treatment using Waterlase MDTM Turbo all-tissue laser therapy
Study NCT06702956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tooth movement
Description: tooth movement us done using wires and brackets
Study NCT05838508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Research participants will be assigned to two exercise conditions.
Study NCT05182008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Online interactive decision aid on method of early abortion
Study NCT05182008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will be directed to the abortion clinic website
Study NCT06516549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping rope and informational pamphlet
Description: The provision of a skipping rope and an informational pamphlet to the intervention arm participants will happen during the participant interview within the overall DASH cohort study. The enumerator conducting the survey interview will provide each participant in the intervention group with a skipping rope and pamphlet and will read a short script explaining how to use the rope, outlining the main benefits of physical activity for adolescents, and asking participants to read the pamphlet in their own time.
Study NCT06236334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELFI lifestyle intervention
Description: A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.
Study NCT04862052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular management of prior implanted coronary drug eluting stent restenosis
Description: Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
Study NCT04862052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular management of prior implanted coronary drug eluting stent restenosis
Description: Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
Study NCT05262023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL593
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Study NCT05262023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Study NCT06362616 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation
Description: Patients will be treated with 5 x 5.2 Gray (Gy) preoperative accelerated partial breast irradiation of the in situ tumor in the breast
Study NCT06362616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery
Description: Patients will be treated with breast conserving surgery.
Study NCT06362616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node procedure
Description: Patients will undergo a (repeat) sentinel node procedure.
Study NCT06362616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy track removal
Description: The biopsy track will be surgically removed.
Study NCT04322383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
Study NCT06515080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near Red Infrascopy
Description: Monitor of regional cerebral oxygen saturation
Study NCT06497101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temperament Based Therapy with Support (TBT-S)
Description: Participants included in the intervention arm will receive TBT-S (5-day treatment) in addition to treatment as usual (TAU)
Study NCT05617898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Three motivational interviewing sessions will target sensitivity to social reward, including subjective evaluation of social interaction, socially rewarding stimuli, and events (e.g., interactions with others, feedback from others).
Study NCT05617898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Didactic Training
Description: The Nutrition didactic training will ask participants to discuss pros and cons of healthy eating habits and how to improve their current eating habits.
Study NCT04840901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Administered SC.
Study NCT05346510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALND Group
Description: ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
Study NCT06131918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol, Alpha lipoic acid, Super oxide dismutase
Description: Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
Study NCT04982575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Description: Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study NCT04982575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 2.4 mg
Description: Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study NCT05820542 — intervention group
Intervention type: OTHER
Intervention: McGrath MAC videolaryngoscope
Description: The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
Study NCT06131918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
Study NCT06131918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
Study NCT06131918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Super Oxide Dismutase
Description: Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
Study NCT05222178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMI-103
Description: HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
Study NCT06535867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mHealth
Description: The mobile health (mHealth) program will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers.
Study NCT04317300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
Study NCT04317300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brief behavioral therapy
Description: brief behavioral therapy
Study NCT05025293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: 100ml Zoledronic acid (5mg/100ml) administered intravenously
Study NCT05445778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine plus Bevacizumab
Description: Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
Study NCT05445778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Participants will receive Bevacizumab 15mg/kg every 3 weeks
Study NCT05025293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: 100ml Zoledronic acid (5mg/100ml) administered intravenously
Study NCT05025293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: 100ml NaCl 9mg/ml administered intravenously
Study NCT04944342 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study NCT05225428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Education
Description: Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
Study NCT05225428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Standard genetic counseling
Study NCT05880485 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: online adaptive radiotherapy
Description: PTV with 5-10 margins covers CTV
Study NCT05365594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ankle Movement Boot
Description: Walking boot used for orthopaedic foot injuries
Study NCT05365594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVENUp Lift
Description: Orthotic shoe lift worn on contralateral foot to increase leg length
Study NCT04820335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured External Memory Aid Treatment (SEMAT)
Description: During the 7 weeks of treatment, the interventionist will teach 3 categories of external memory aids (calendars, timers, notes) following an already-developed detailed treatment manual (described here briefly).~Week 1: Introduction of External Memory Aid Treatment and Person-Centered Goal Setting. Weeks 2-7. In the next six weeks, three categories of external memory aids will be taught: calendars, timers, and notes. The focus of the first session will be how to use the strategies, and the second session will build awareness of when to use these strategies during everyday tasks. Within each category, three types of strategies will be taught to participants. Within each session, learning phases will follow training stages from compensatory learning theory: 1) acquisition phase, 2) application phase, and 3) an adaptation phase.
Study NCT06234605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-7366
Description: HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.
Study NCT06234605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan is a potent and selective HIF-2α inhibitor
Study NCT06580782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate 500 MG
Description: Calcium Carbonate 500mg, orally, every 4 hours.
Study NCT06580782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose Synthetic Pitocin
Description: The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.
Study NCT06580782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Synthetic Pitocin
Description: The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.
Study NCT04982575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide 2.4 mg
Description: Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study NCT04982575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide 2.4 mg
Description: Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study NCT04982575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study NCT04982575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (cagrilintide)
Description: Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study NCT06025487 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bexsero
Description: two doses of Bexsero are applied intramuscularly with a one-month interval between doses
Study NCT04741945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 2000 mg/day metformin for 12 months (1000 mg b.i.d.) with a slow up-titration six weeks prior to full dose treatment.
Study NCT05722340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy
Description: An epidural anaesthesia associated with mild sedation requiring no ventilation is used.